Semalytix key facts
- Developer of an AI-based evidence and analytics generation platform designed to capture and generate online patient experiences in multiple therapy areas like oncology, inflammatory diseases,…
- It has raised $14.3M; the latest was Later Stage VC ($6.6M) in Oct 2025.
- Notable investors include b2venture, NRW.Bank, Fly Ventures, Holland Capital (Private Equity), Bielefeld University — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Semalytix: the Monday email on marks, rounds and moves
Semalytix funding rounds
No funding rounds for Semalytix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Semalytix investors
7 investors are on record for Semalytix, including b2venture, NRW.Bank, Fly Ventures and Holland Capital (Private Equity).
About Semalytix
Developer of an AI-based evidence and analytics generation platform designed to capture and generate online patient experiences in multiple therapy areas like oncology, inflammatory diseases, metabolism, and respiratory systems. The company's platform gathers data from patient forums, social media, and other online sources on everyday medication experiences to provide insights, enabling medical and pharmaceutical sector industries make informed decisions that directly impact the success rates of treatment outcomes.
- Sector
- Healthcare
- HQ
- Bielefeld, Germany
- Founded
- 2015
- Employees
- 75
- Website
- semalytix.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Semalytix doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.